<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>immunology</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>immunology | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants
Authors: Wang, Q.; Guo, Y.; Bowen, A.; Mellis, I. A.; Valdez, R.; Gherasim, C.; Gordon, A.; Liu, L.; Ho, D. D.
Score: 1103.1, Published: 2023-12-06 DOI: 10.1101/2023.11.26.568730
COVID-19 vaccines have recently been updated with the spike protein of SARS-CoV-2 XBB.1.5 subvariant alone, but their immunogenicity in humans has yet to be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/immunology/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="immunology" />
<meta property="og:description" content="XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants
Authors: Wang, Q.; Guo, Y.; Bowen, A.; Mellis, I. A.; Valdez, R.; Gherasim, C.; Gordon, A.; Liu, L.; Ho, D. D.
Score: 1103.1, Published: 2023-12-06 DOI: 10.1101/2023.11.26.568730
COVID-19 vaccines have recently been updated with the spike protein of SARS-CoV-2 XBB.1.5 subvariant alone, but their immunogenicity in humans has yet to be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/immunology/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-12-10T10:37:48+00:00" />
<meta property="article:modified_time" content="2023-12-10T10:37:48+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="immunology"/>
<meta name="twitter:description" content="XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants
Authors: Wang, Q.; Guo, Y.; Bowen, A.; Mellis, I. A.; Valdez, R.; Gherasim, C.; Gordon, A.; Liu, L.; Ho, D. D.
Score: 1103.1, Published: 2023-12-06 DOI: 10.1101/2023.11.26.568730
COVID-19 vaccines have recently been updated with the spike protein of SARS-CoV-2 XBB.1.5 subvariant alone, but their immunogenicity in humans has yet to be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "immunology",
      "item": "https://trxiv.yorks0n.com/posts/immunology/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "immunology",
  "name": "immunology",
  "description": "XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants\nAuthors: Wang, Q.; Guo, Y.; Bowen, A.; Mellis, I. A.; Valdez, R.; Gherasim, C.; Gordon, A.; Liu, L.; Ho, D. D.\nScore: 1103.1, Published: 2023-12-06 DOI: 10.1101/2023.11.26.568730\nCOVID-19 vaccines have recently been updated with the spike protein of SARS-CoV-2 XBB.1.5 subvariant alone, but their immunogenicity in humans has yet to be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding.",
  "keywords": [
    
  ],
  "articleBody": " XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants\nAuthors: Wang, Q.; Guo, Y.; Bowen, A.; Mellis, I. A.; Valdez, R.; Gherasim, C.; Gordon, A.; Liu, L.; Ho, D. D.\nScore: 1103.1, Published: 2023-12-06 DOI: 10.1101/2023.11.26.568730\nCOVID-19 vaccines have recently been updated with the spike protein of SARS-CoV-2 XBB.1.5 subvariant alone, but their immunogenicity in humans has yet to be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report that administration of an updated monovalent mRNA vaccine (XBB.1.5 MV) to uninfected individuals boosted serum virus-neutralization antibodies significantly against not only XBB.1.5 (27.0-fold) and the currently dominant EG.5.1 (27.6-fold) but also key emergent viruses like HV.1, HK.3, JD.1.1, and JN.1 (13.3-to-27.4-fold). In individuals previously infected by an Omicron subvariant, serum neutralizing titers were boosted to highest levels (1,504-to-22,978) against all viral variants tested. While immunological imprinting was still evident with the updated vaccines, it was not nearly as severe as the previously authorized bivalent BA.5 vaccine. Our findings strongly support the official recommendation to widely apply the updated COVID-19 vaccines to further protect the public.\nPersistent immune imprinting after XBB.1.5 COVID vaccination in humans\nAuthors: Tortorici, M. A.; Addetia, A.; Seo, A. J.; Brown, J.; Sprouse, K.; Logue, J.; Clarke, E.; Franko, N.; Chu, H.; Veesler, D.\nScore: 240.1, Published: 2023-11-30 DOI: 10.1101/2023.11.28.569129\nImmune imprinting - also known as original antigenic sin - describes how the first exposure to a virus shapes the immunological outcome of subsequent exposures to antigenically related strains. SARS-CoV-2 Omicron breakthrough infections and bivalent COVID-19 vaccination were shown to primarily recall cross-reactive memory B cells and antibodies induced by prior mRNA vaccination with the Wuhan-Hu-1 spike rather than priming naive B cells that recognize Omicron-specific epitopes. These findings underscored a strong immune imprinting resulting from repeated Wuhan-Hu-1 spike exposures. To understand if immune imprinting can be overcome, we investigated memory and plasma antibody responses after administration of the updated XBB.1.5 COVID mRNA vaccine booster. Our data show that the XBB.1.5 booster elicits neutralizing antibody responses against current variants that are dominated by recall of pre-existing memory B cells previously induced by the Wuhan-Hu-1 spike. These results indicate that immune imprinting persists even after multiple exposures to Omicron spikes through vaccination and infection, including post XBB.1.5 spike booster mRNA vaccination, which will need to be considered to guide the design of future vaccine boosters.\nThe immune landscape of the inflamed joint defined by spectral flow cytometry\nAuthors: Attrill, M. H.; Shinko, D.; Alexiou, V.; Kartawinata, M.; Wedderburn, L. R.; CHARMS study, ; JIAP study, ; Pesenacker, A. M.\nScore: 10.0, Published: 2023-12-04 DOI: 10.1101/2023.11.30.569010\nCellular phenotype and function are altered in different microenvironments. For targeted therapies it is important to understand site-specific cellular adaptations. Juvenile Idiopathic Arthritis (JIA) is characterised by joint inflammation, with frequent inadequate treatment responses. To comprehensively assess the inflammatory immune landscape, we designed a 37-parameter spectral flow cytometry panel delineating mononuclear cells from JIA synovial fluid (SF), compared to JIA and healthy control blood. Synovial monocytes and NK cells lack the Fc-receptor CD16, suggesting antibody-mediated targeting may be ineffective. B cells and DCs, both in small frequencies in SF, undergo maturation with high 4-1BB, CD71, CD39 expression, supporting T cell activation. SF effector and regulatory T cells were highly active with newly described co-receptor combinations that may alter function, and suggestion of metabolic reprogramming via CD71, TNFR2 and PD-1. Most SF effector phenotypes, as well as an identified CD4-Foxp3+ T cell population, were restricted to the inflamed joint, yet specific SF-predominant Treg (CD4+Foxp3+) subpopulations were increased in blood of active but not inactive JIA, suggesting possible recirculation and loss of immunoregulation at distal sites. This first comprehensive dataset of the site-specific inflammatory landscape at protein level will inform functional studies and the development of targeted therapeutics to restore immunoregulatory balance and achieve remission in JIA. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=146 SRC=\"FIGDIR/small/569010v1_ufig1.gif\" ALT=\"Figure 1\"\u003e View larger version (44K): org.highwire.dtl.DTLVardef@f3234corg.highwire.dtl.DTLVardef@926587org.highwire.dtl.DTLVardef@147ae78org.highwire.dtl.DTLVardef@10f5b67_HPS_FORMAT_FIGEXP M_FIG C_FIG\nInnate extracellular Hsp70 inflammatory properties are mediated by the interaction of Siglec-E and LOX-1 receptors\nAuthors: Borges, T. J.; Lima, K.; Murshid, A.; Lape, I. T.; Zhao, Y.; Rigo, M. M.; Lang, B. J.; Siddiqui, S. S.; Hui, E.; Riella, L. V.; Bonorino, C.; Calderwood, S. K.\nScore: 8.6, Published: 2023-12-04 DOI: 10.1101/2023.12.01.569623\nInnate immune responses to cell damage-associated molecular patterns induce a controlled degree of inflammation, ideally avoiding the promotion of intense unwanted inflammatory adverse events. When released by damaged cells, Hsp70 can stimulate different responses that range from immune activation to immune suppression. The effects of Hsp70 are mediated through innate receptors expressed primarily by myeloid cells, such as dendritic cells (DCs). The regulatory innate receptors that bind to extracellular mouse Hsp70 (mHsp70) are not fully characterized, and neither are their potential interactions with activating innate receptors. Here, we describe that extracellular mHsp70 interacts with a receptor complex formed by inhibitory Siglec-E and activating LOX-1 on DCs. We also find that this interaction takes place within lipid microdomains, and Siglec-E acts as a negative regulator of LOX-1-mediated innate activation upon mHsp70 or oxidized LDL binding. Thus, HSP70 can both bind to and modulate the interaction of inhibitory and activating innate receptors on the cell surface. These findings add another dimension of regulatory mechanism to how self-molecules contribute to dampening of exacerbated inflammatory responses.\nMemory B cells dominate the early antibody-secreting cell response to SARS-CoV-2 mRNA vaccination in naive individuals independently of their antibody affinity\nAuthors: Li, Z.; Obraztsova, A.; Shang, F.; Oludada, O. E.; Malapit, J.; Busch, K.; van Straaten, M.; Stebbins, E.; Murugan, R.; Wardemann, H.\nScore: 7.1, Published: 2023-12-03 DOI: 10.1101/2023.12.01.569639\nMemory B cells (MBCs) formed over the individuals lifetime constitute nearly half of the adult peripheral blood B cell repertoire in humans. To assess their response to novel antigens, we tracked the origin and followed the differentiation paths of MBCs in the early anti-S response to mRNA vaccination in SARS-CoV-2-naive individuals on single-cell and monoclonal antibody level. Newly generated and pre-existing MBCs differed in their differentiation paths despite similar levels of SARS-CoV-2 and common corona virus S-reactivity. Pre-existing highly mutated MBCs showed no signs of germinal center re-entry and rapidly developed into mature antibody secreting cells (ASCs). In contrast, newly generated MBCs derived from naive precursors showed strong signs of antibody affinity maturation before differentiating into ASCs. Thus, although pre-existing human MBCs have an intrinsic propensity to differentiate into ASCs, the quality of the anti-S antibody and MBC response improved through the clonal selection and affinity maturation of naive precursors. HighlightsO_LImRNA vaccination of SARS-CoV-2 naive individuals recruits naive and pre-existing MBCs with similar levels of S-reactivity into the response C_LIO_LIS-reactive naive but not pre-existing MBCs undergo affinity maturation C_LIO_LIS-reactive pre-existing MBCs dominate the early ASC response independent of their antigen affinity C_LIO_LIHigh-affinity S-reactive MBCs and ASCs develop over time and originate from affinity matured naive precursors C_LI\npan-MHC and cross-Species Prediction of T Cell Receptor-Antigen Binding\nAuthors: Han, Y.; Yang, Y.; Tian, Y.; Fattah, F. J.; Itzstein, M. S. v.; Zhang, M.; Kang, X.; Yang, D. M.; Liu, J.; Xue, Y.; Liang, C.; Raman, I.; Zhu, C.; Xiao, O.; Hu, Y.; Dowell, J. E.; Homsi, J.; Rashdan, S.; Yang, S.; Gwin, M. E.; Hsiehchen, D.; Gloria-McCutchen, Y.; Pan, K.; Wu, F.; Gibbons, D.; Wang, X.; Yee, C.; Huang, J.; Reuben, A.; Cheng, C.; Zhang, J.; Gerber, D. E.; Wang, T.\nScore: 7.0, Published: 2023-12-04 DOI: 10.1101/2023.12.01.569599\nProfiling the binding of T cell receptors (TCRs) of T cells to antigenic peptides presented by MHC proteins is one of the most important unsolved problems in modern immunology. Traditional experimental methods to probe TCR-antigen interactions are slow, labor-intensive, costly, and yield moderate throughput. To address this problem, we developed pMTnet-omni, an Artificial Intelligence (AI) system based on hybrid protein sequence and structure information, to predict the pairing of TCRs of {beta} T cells with peptide-MHC complexes (pMHCs). pMTnet-omni is capable of handling peptides presented by both class I and II pMHCs, and capable of handling both human and mouse TCR-pMHC pairs, through large-scale information sharing and this hybrid design. pMTnet-omni achieves a high overall Area Under the Curve of Receiver Operator Characteristics (AUROC) of 0.89, which surpasses competing tools by a large margin. We showed that pMTnet-omni can distinguish binding affinity of TCRs with similar sequences. Across a range of datasets from various biological contexts, pMTnet-omni characterized the longitudinal evolution and spatial heterogeneity of TCR-pMHC interactions and their functional impact. We successfully developed a biomarker based on pMTnet-omni for predicting immune-related adverse events of immune checkpoint inhibitor (ICI) treatment in a cohort of 57 ICI-treated patients. pMTnet-omni represents a major advance towards developing a clinically usable AI system for TCR-pMHC pairing prediction that can aid the design and implementation of TCR-based immunotherapeutics.\nDurable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates\nAuthors: Moliva, J. I.; Andrew, S. F.; Flynn, B. J.; Wagner, D. A.; Foulds, K. E.; Gagne, M.; Flebbe, D. R.; Lamb, E.; Provost, S.; Marquez, J.; Mychalowych, A.; Lorag, C.; Honeycutt, C. C.; Burnett, M. R.; McCormick, L.; Henry, A. R.; Godbole, S.; Davis-Gardner, M. E.; Minai, M.; Bok, K. W.; Nagata, B. M.; Todd, J.-P. M.; McCarthy, E.; Dodson, A.; Kouneski, K.; Cook, A.; Pessaint, L.; Van Ry, A.; Valentin, D.; Young, S.; Littman, Y.; Boon, A. C. M.; Suthar, M. S.; Lewis, M. G.; Andersen, H.; Alves, D. A.; Woodward, R.; Leuzzi, A.; Vitelli, A.; Colloca, S.; Folgori, A.; Raggiolli, A.; Capone, S.; Nason\nScore: 24.7, Published: 2023-11-22 DOI: 10.1101/2023.11.22.567930\nSARS-CoV-2 continues to pose a global threat, and current vaccines, while effective against severe illness, fall short in preventing transmission. To address this challenge, theres a need for vaccines that induce mucosal immunity and can rapidly control the virus. In this study, we demonstrate that a single immunization with a novel gorilla adenovirus-based vaccine (GRAd) carrying the pre-fusion stabilized Spike protein (S-2P) in non-human primates provided protective immunity for over one year against the BA.5 variant of SARS-CoV-2. A prime-boost regimen using GRAd followed by adjuvanted S-2P (GRAd+S-2P) accelerated viral clearance in both the lower and upper airways. GRAd delivered via aerosol (GRAd(AE)+S-2P) modestly improved protection compared to its matched intramuscular regimen, but showed dramatically superior boosting by mRNA and, importantly, total virus clearance in the upper airway by day 4 post infection. GrAd vaccination regimens elicited robust and durable systemic and mucosal antibody responses to multiple SARS-CoV-2 variants, but only GRAd(AE)+S-2P generated long-lasting T cell responses in the lung. This research underscores the flexibility of the GRAd vaccine platform to provide durable immunity against SARS-CoV-2 in both the lower and upper airways.\nAn IL-2 mutein increases IL-10 and CTLA-4-dependent suppression of dendritic cells by regulatory T cells\nAuthors: Jamison, B. L.; Lawrance, M.; Wang, C. J.; DeBerg, H. A.; Sansom, D.; Gavin, M. A.; Walker, L. S. K.; Campbell, D. J.\nScore: 6.3, Published: 2023-12-04 DOI: 10.1101/2023.12.01.569613\nInterleukin-2 (IL-2) variants with increased CD25 dependence that selectively expand Foxp3+ regulatory T (TR) cells are in clinical trials for treating inflammatory diseases. Using an Fc-fused IL-2 mutein (Fc.IL-2 mutein) we developed that prevents diabetes in non-obese diabetic (NOD) mice, we show that Fc.IL-2 mutein induced an activated TR population with elevated proliferation, a transcriptional program associated with Stat5- and TCR-dependent gene modules, and high IL-10 and CTLA-4 expression. Increased IL-10 signaling limited surface MHC class II upregulation during conventional dendritic cell (cDC) maturation, while increased CTLA-4-dependent transendocytosis led to the transfer of CD80 and CD86 costimulatory ligands from maturing cDCs to TR cells. In NOD mice, Fc.IL-2 mutein treatment promoted the suppression of cDCs in the inflamed pancreas and pancreatic lymph nodes resulting in T cell anergy. Thus, IL-2 mutein-expanded TR cells have enhanced functional properties and restrict cDC function, offering promise for targeted immunotherapy use in autoimmune disease.\nInterpretable Inflammation Landscape of Circulating Immune cells\nAuthors: Jimenez-Gracia, L.; Maspero, D.; Aguilar-Fernandez, S.; Craighero, F.; Ruiz, S.; Marchese, D.; Caratu, G.; Elosua-Bayes, M.; Abdalfatah, M.; Sanzo-Machuca, A.; M. Corraliza, A.; Massoni-Badosa, R.; A. Tran, H.; Normand, R.; Nestor, J.; Hong, Y.; Kole, T.; van der Velde, P.; Alleblas, F.; Pedretti, F.; Aterido, A.; Banchero, M.; Soriano, G.; Roman, E.; van den Berge, M.; Salas, A.; Carrascosa, J. M.; Fernandez Nebro, A.; Domenech, E.; Canete, J.; Tornero, J.; Perez-Gisbert, J.; Choy, E.; Girolomoni, G.; Siegmund, B.; Julia, A.; Serra, V.; Elosua, R.; Tejpar, S.; Vidal, S.; Nawijn, M. C.; Marsal\nScore: 56.0, Published: 2023-11-28 DOI: 10.1101/2023.11.28.568839\nInflammation is a biological phenomenon involved in a wide variety of physiological and pathological processes. Although a controlled inflammatory response is beneficial for restoring homeostasis, it can become unfavorable if dysregulated. In recent years, major progress has been made in characterizing acute and chronic inflammation in specific diseases. However, a global, holistic understanding of inflammation is still elusive. This is particularly intriguing, considering the crucial function of inflammation for human health and its potential for modern medicine if fully deciphered. Here, we leverage advances in the field of single-cell genomics to delineate the full spectrum of circulating immune cell activation underlying inflammatory processes during infection, immune-mediated inflammatory diseases and cancer. Our single-cell atlas of \u003e2 million peripheral blood mononuclear cells from 356 patients and 18 diseases allowed us to learn a foundation model of inflammation in circulating immune cells. The atlas expanded our current knowledge of the biology of inflammation of acute (e.g. inflammatory bowel disease, sepsis) and chronic (e.g. cirrhosis, asthma, and chronic obstructive pulmonary disease) disease processes and laid the foundation to develop a precision medicine framework using unsupervised as well as explainable machine learning. Beyond a disease-centered classification, we charted altered activity of inflammatory molecules in peripheral blood cells, depicting functional biomarkers to further understand mechanisms of inflammation. Finally, we have laid the groundwork for developing precision medicine diagnostic tools for patients experiencing severe acute or chronic inflammation by learning a classifier for inflammatory diseases, presenting cells in circulation as a powerful resource for patient stratification.\nFast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure\nAuthors: Yang, S.; Yu, Y.; Xu, Y.; Jian, F.; Song, W.; Yisimayi, A.; Wang, P.; Wang, J.; Liu, J.; Yu, L.; Niu, X.; Wang, J.; Wang, Y.; Shao, F.; Jin, R.; Wang, Y.; Cao, Y.\nScore: 328.8, Published: 2023-11-17 DOI: 10.1101/2023.11.13.566860\nWhile the BA.2.86 variant demonstrated significant antigenic drift and enhanced ACE2 binding affinity, its ability to evade humoral immunity was relatively moderate compared to dominant strains like EG.5 and HK.3. However, the emergence of a new subvariant, JN.1 (BA.2.86.1.1), which possesses an additional spike mutation, L455S, compared to BA.2.86, showed a markedly increased prevalence in Europe and North America, especially in France. Here, we found that L455S of JN.1 significantly enhances immune evasion capabilities at the expense of reduced ACE2 binding affinity. This mutation enables JN.1 to effectively evade Class 1 neutralizing antibodies, offsetting BA.2.86s susceptibility and thus allowing it to outcompete both its precursor BA.2.86 and the prevailing variants HV.1 (XBB.1.5+L452R+F456L) and JD.1.1 (XBB.1.5+L455F+F456L+A475V) in terms of humoral immune evasion. The rapid evolution from BA.2.86 to JN.1, similar to the earlier transition from BA.2.75 to CH.1.1, highlights the importance of closely monitoring strains with high ACE2 binding affinity and distinct antigenicity, despite their temporarily unremarkable immune evasion capabilities. Such strains could survive and transmit at low levels, since their large antigenic distance to dominant strains allow them to target distinct populations and accumulate immune-evasive mutations rapidly, often at the cost of receptor binding affinity.\n",
  "wordCount" : "2565",
  "inLanguage": "en",
  "datePublished": "2023-12-10T10:37:48Z",
  "dateModified": "2023-12-10T10:37:48Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/immunology/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      immunology
    </h1>
    <div class="post-meta">&lt;span&gt;updated on December 10, 2023&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.11.26.568730">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.11.26.568730" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.11.26.568730">
        <p class="paperTitle">XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.11.26.568730" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.11.26.568730" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Wang, Q.; Guo, Y.; Bowen, A.; Mellis, I. A.; Valdez, R.; Gherasim, C.; Gordon, A.; Liu, L.; Ho, D. D.</p>
        <p class="info">Score: 1103.1, Published: 2023-12-06 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.11.26.568730' target='https://doi.org/10.1101/2023.11.26.568730'> 10.1101/2023.11.26.568730</a></p>
        <p class="abstract">COVID-19 vaccines have recently been updated with the spike protein of SARS-CoV-2 XBB.1.5 subvariant alone, but their immunogenicity in humans has yet to be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report that administration of an updated monovalent mRNA vaccine (XBB.1.5 MV) to uninfected individuals boosted serum virus-neutralization antibodies significantly against not only XBB.1.5 (27.0-fold) and the currently dominant EG.5.1 (27.6-fold) but also key emergent viruses like HV.1, HK.3, JD.1.1, and JN.1 (13.3-to-27.4-fold). In individuals previously infected by an Omicron subvariant, serum neutralizing titers were boosted to highest levels (1,504-to-22,978) against all viral variants tested. While immunological imprinting was still evident with the updated vaccines, it was not nearly as severe as the previously authorized bivalent BA.5 vaccine. Our findings strongly support the official recommendation to widely apply the updated COVID-19 vaccines to further protect the public.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.11.28.569129">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.11.28.569129" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.11.28.569129">
        <p class="paperTitle">Persistent immune imprinting after XBB.1.5 COVID vaccination in humans</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.11.28.569129" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.11.28.569129" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Tortorici, M. A.; Addetia, A.; Seo, A. J.; Brown, J.; Sprouse, K.; Logue, J.; Clarke, E.; Franko, N.; Chu, H.; Veesler, D.</p>
        <p class="info">Score: 240.1, Published: 2023-11-30 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.11.28.569129' target='https://doi.org/10.1101/2023.11.28.569129'> 10.1101/2023.11.28.569129</a></p>
        <p class="abstract">Immune imprinting - also known as  original antigenic sin - describes how the first exposure to a virus shapes the immunological outcome of subsequent exposures to antigenically related strains. SARS-CoV-2 Omicron breakthrough infections and bivalent COVID-19 vaccination were shown to primarily recall cross-reactive memory B cells and antibodies induced by prior mRNA vaccination with the Wuhan-Hu-1 spike rather than priming naive B cells that recognize Omicron-specific epitopes. These findings underscored a strong immune imprinting resulting from repeated Wuhan-Hu-1 spike exposures. To understand if immune imprinting can be overcome, we investigated memory and plasma antibody responses after administration of the updated XBB.1.5 COVID mRNA vaccine booster. Our data show that the XBB.1.5 booster elicits neutralizing antibody responses against current variants that are dominated by recall of pre-existing memory B cells previously induced by the Wuhan-Hu-1 spike. These results indicate that immune imprinting persists even after multiple exposures to Omicron spikes through vaccination and infection, including post XBB.1.5 spike booster mRNA vaccination, which will need to be considered to guide the design of future vaccine boosters.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.11.30.569010">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.11.30.569010" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.11.30.569010">
        <p class="paperTitle">The immune landscape of the inflamed joint defined by spectral flow cytometry</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.11.30.569010" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.11.30.569010" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Attrill, M. H.; Shinko, D.; Alexiou, V.; Kartawinata, M.; Wedderburn, L. R.; CHARMS study,  ; JIAP study,  ; Pesenacker, A. M.</p>
        <p class="info">Score: 10.0, Published: 2023-12-04 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.11.30.569010' target='https://doi.org/10.1101/2023.11.30.569010'> 10.1101/2023.11.30.569010</a></p>
        <p class="abstract">Cellular phenotype and function are altered in different microenvironments. For targeted therapies it is important to understand site-specific cellular adaptations. Juvenile Idiopathic Arthritis (JIA) is characterised by joint inflammation, with frequent inadequate treatment responses. To comprehensively assess the inflammatory immune landscape, we designed a 37-parameter spectral flow cytometry panel delineating mononuclear cells from JIA synovial fluid (SF), compared to JIA and healthy control blood. Synovial monocytes and NK cells lack the Fc-receptor CD16, suggesting antibody-mediated targeting may be ineffective. B cells and DCs, both in small frequencies in SF, undergo maturation with high 4-1BB, CD71, CD39 expression, supporting T cell activation. SF effector and regulatory T cells were highly active with newly described co-receptor combinations that may alter function, and suggestion of metabolic reprogramming via CD71, TNFR2 and PD-1. Most SF effector phenotypes, as well as an identified CD4-Foxp3&#43; T cell population, were restricted to the inflamed joint, yet specific SF-predominant Treg (CD4&#43;Foxp3&#43;) subpopulations were increased in blood of active but not inactive JIA, suggesting possible recirculation and loss of immunoregulation at distal sites. This first comprehensive dataset of the site-specific inflammatory landscape at protein level will inform functional studies and the development of targeted therapeutics to restore immunoregulatory balance and achieve remission in JIA.

Graphical Abstract

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=146 SRC=&#34;FIGDIR/small/569010v1_ufig1.gif&#34; ALT=&#34;Figure 1&#34;&gt;
View larger version (44K):
org.highwire.dtl.DTLVardef@f3234corg.highwire.dtl.DTLVardef@926587org.highwire.dtl.DTLVardef@147ae78org.highwire.dtl.DTLVardef@10f5b67_HPS_FORMAT_FIGEXP  M_FIG C_FIG</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.12.01.569623">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.12.01.569623" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.12.01.569623">
        <p class="paperTitle">Innate extracellular Hsp70 inflammatory properties are mediated by the interaction of Siglec-E and LOX-1 receptors</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.12.01.569623" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.12.01.569623" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Borges, T. J.; Lima, K.; Murshid, A.; Lape, I. T.; Zhao, Y.; Rigo, M. M.; Lang, B. J.; Siddiqui, S. S.; Hui, E.; Riella, L. V.; Bonorino, C.; Calderwood, S. K.</p>
        <p class="info">Score: 8.6, Published: 2023-12-04 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.12.01.569623' target='https://doi.org/10.1101/2023.12.01.569623'> 10.1101/2023.12.01.569623</a></p>
        <p class="abstract">Innate immune responses to cell damage-associated molecular patterns induce a controlled degree of inflammation, ideally avoiding the promotion of intense unwanted inflammatory adverse events. When released by damaged cells, Hsp70 can stimulate different responses that range from immune activation to immune suppression. The effects of Hsp70 are mediated through innate receptors expressed primarily by myeloid cells, such as dendritic cells (DCs). The regulatory innate receptors that bind to extracellular mouse Hsp70 (mHsp70) are not fully characterized, and neither are their potential interactions with activating innate receptors. Here, we describe that extracellular mHsp70 interacts with a receptor complex formed by inhibitory Siglec-E and activating LOX-1 on DCs. We also find that this interaction takes place within lipid microdomains, and Siglec-E acts as a negative regulator of LOX-1-mediated innate activation upon mHsp70 or oxidized LDL binding. Thus, HSP70 can both bind to and modulate the interaction of inhibitory and activating innate receptors on the cell surface. These findings add another dimension of regulatory mechanism to how self-molecules contribute to dampening of exacerbated inflammatory responses.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.12.01.569639">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.12.01.569639" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.12.01.569639">
        <p class="paperTitle">Memory B cells dominate the early antibody-secreting cell response to SARS-CoV-2 mRNA vaccination in naive individuals independently of their antibody affinity</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.12.01.569639" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.12.01.569639" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Li, Z.; Obraztsova, A.; Shang, F.; Oludada, O. E.; Malapit, J.; Busch, K.; van Straaten, M.; Stebbins, E.; Murugan, R.; Wardemann, H.</p>
        <p class="info">Score: 7.1, Published: 2023-12-03 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.12.01.569639' target='https://doi.org/10.1101/2023.12.01.569639'> 10.1101/2023.12.01.569639</a></p>
        <p class="abstract">Memory B cells (MBCs) formed over the individuals lifetime constitute nearly half of the adult peripheral blood B cell repertoire in humans. To assess their response to novel antigens, we tracked the origin and followed the differentiation paths of MBCs in the early anti-S response to mRNA vaccination in SARS-CoV-2-naive individuals on single-cell and monoclonal antibody level. Newly generated and pre-existing MBCs differed in their differentiation paths despite similar levels of SARS-CoV-2 and common corona virus S-reactivity. Pre-existing highly mutated MBCs showed no signs of germinal center re-entry and rapidly developed into mature antibody secreting cells (ASCs). In contrast, newly generated MBCs derived from naive precursors showed strong signs of antibody affinity maturation before differentiating into ASCs. Thus, although pre-existing human MBCs have an intrinsic propensity to differentiate into ASCs, the quality of the anti-S antibody and MBC response improved through the clonal selection and affinity maturation of naive precursors.

HighlightsO_LImRNA vaccination of SARS-CoV-2 naive individuals recruits naive and pre-existing MBCs with similar levels of S-reactivity into the response
C_LIO_LIS-reactive naive but not pre-existing MBCs undergo affinity maturation
C_LIO_LIS-reactive pre-existing MBCs dominate the early ASC response independent of their antigen affinity
C_LIO_LIHigh-affinity S-reactive MBCs and ASCs develop over time and originate from affinity matured naive precursors
C_LI</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.12.01.569599">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.12.01.569599" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.12.01.569599">
        <p class="paperTitle">pan-MHC and cross-Species Prediction of T Cell Receptor-Antigen Binding</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.12.01.569599" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.12.01.569599" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Han, Y.; Yang, Y.; Tian, Y.; Fattah, F. J.; Itzstein, M. S. v.; Zhang, M.; Kang, X.; Yang, D. M.; Liu, J.; Xue, Y.; Liang, C.; Raman, I.; Zhu, C.; Xiao, O.; Hu, Y.; Dowell, J. E.; Homsi, J.; Rashdan, S.; Yang, S.; Gwin, M. E.; Hsiehchen, D.; Gloria-McCutchen, Y.; Pan, K.; Wu, F.; Gibbons, D.; Wang, X.; Yee, C.; Huang, J.; Reuben, A.; Cheng, C.; Zhang, J.; Gerber, D. E.; Wang, T.</p>
        <p class="info">Score: 7.0, Published: 2023-12-04 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.12.01.569599' target='https://doi.org/10.1101/2023.12.01.569599'> 10.1101/2023.12.01.569599</a></p>
        <p class="abstract">Profiling the binding of T cell receptors (TCRs) of T cells to antigenic peptides presented by MHC proteins is one of the most important unsolved problems in modern immunology. Traditional experimental methods to probe TCR-antigen interactions are slow, labor-intensive, costly, and yield moderate throughput. To address this problem, we developed pMTnet-omni, an Artificial Intelligence (AI) system based on hybrid protein sequence and structure information, to predict the pairing of TCRs of {beta} T cells with peptide-MHC complexes (pMHCs). pMTnet-omni is capable of handling peptides presented by both class I and II pMHCs, and capable of handling both human and mouse TCR-pMHC pairs, through large-scale information sharing and this hybrid design. pMTnet-omni achieves a high overall Area Under the Curve of Receiver Operator Characteristics (AUROC) of 0.89, which surpasses competing tools by a large margin. We showed that pMTnet-omni can distinguish binding affinity of TCRs with similar sequences. Across a range of datasets from various biological contexts, pMTnet-omni characterized the longitudinal evolution and spatial heterogeneity of TCR-pMHC interactions and their functional impact. We successfully developed a biomarker based on pMTnet-omni for predicting immune-related adverse events of immune checkpoint inhibitor (ICI) treatment in a cohort of 57 ICI-treated patients. pMTnet-omni represents a major advance towards developing a clinically usable AI system for TCR-pMHC pairing prediction that can aid the design and implementation of TCR-based immunotherapeutics.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.11.22.567930">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.11.22.567930" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.11.22.567930">
        <p class="paperTitle">Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.11.22.567930" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.11.22.567930" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Moliva, J. I.; Andrew, S. F.; Flynn, B. J.; Wagner, D. A.; Foulds, K. E.; Gagne, M.; Flebbe, D. R.; Lamb, E.; Provost, S.; Marquez, J.; Mychalowych, A.; Lorag, C.; Honeycutt, C. C.; Burnett, M. R.; McCormick, L.; Henry, A. R.; Godbole, S.; Davis-Gardner, M. E.; Minai, M.; Bok, K. W.; Nagata, B. M.; Todd, J.-P. M.; McCarthy, E.; Dodson, A.; Kouneski, K.; Cook, A.; Pessaint, L.; Van Ry, A.; Valentin, D.; Young, S.; Littman, Y.; Boon, A. C. M.; Suthar, M. S.; Lewis, M. G.; Andersen, H.; Alves, D. A.; Woodward, R.; Leuzzi, A.; Vitelli, A.; Colloca, S.; Folgori, A.; Raggiolli, A.; Capone, S.; Nason</p>
        <p class="info">Score: 24.7, Published: 2023-11-22 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.11.22.567930' target='https://doi.org/10.1101/2023.11.22.567930'> 10.1101/2023.11.22.567930</a></p>
        <p class="abstract">SARS-CoV-2 continues to pose a global threat, and current vaccines, while effective against severe illness, fall short in preventing transmission. To address this challenge, theres a need for vaccines that induce mucosal immunity and can rapidly control the virus. In this study, we demonstrate that a single immunization with a novel gorilla adenovirus-based vaccine (GRAd) carrying the pre-fusion stabilized Spike protein (S-2P) in non-human primates provided protective immunity for over one year against the BA.5 variant of SARS-CoV-2. A prime-boost regimen using GRAd followed by adjuvanted S-2P (GRAd&#43;S-2P) accelerated viral clearance in both the lower and upper airways. GRAd delivered via aerosol (GRAd(AE)&#43;S-2P) modestly improved protection compared to its matched intramuscular regimen, but showed dramatically superior boosting by mRNA and, importantly, total virus clearance in the upper airway by day 4 post infection. GrAd vaccination regimens elicited robust and durable systemic and mucosal antibody responses to multiple SARS-CoV-2 variants, but only GRAd(AE)&#43;S-2P generated long-lasting T cell responses in the lung. This research underscores the flexibility of the GRAd vaccine platform to provide durable immunity against SARS-CoV-2 in both the lower and upper airways.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.12.01.569613">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.12.01.569613" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.12.01.569613">
        <p class="paperTitle">An IL-2 mutein increases IL-10 and CTLA-4-dependent suppression of dendritic cells by regulatory T cells</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.12.01.569613" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.12.01.569613" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Jamison, B. L.; Lawrance, M.; Wang, C. J.; DeBerg, H. A.; Sansom, D.; Gavin, M. A.; Walker, L. S. K.; Campbell, D. J.</p>
        <p class="info">Score: 6.3, Published: 2023-12-04 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.12.01.569613' target='https://doi.org/10.1101/2023.12.01.569613'> 10.1101/2023.12.01.569613</a></p>
        <p class="abstract">Interleukin-2 (IL-2) variants with increased CD25 dependence that selectively expand Foxp3&#43; regulatory T (TR) cells are in clinical trials for treating inflammatory diseases. Using an Fc-fused IL-2 mutein (Fc.IL-2 mutein) we developed that prevents diabetes in non-obese diabetic (NOD) mice, we show that Fc.IL-2 mutein induced an activated TR population with elevated proliferation, a transcriptional program associated with Stat5- and TCR-dependent gene modules, and high IL-10 and CTLA-4 expression. Increased IL-10 signaling limited surface MHC class II upregulation during conventional dendritic cell (cDC) maturation, while increased CTLA-4-dependent transendocytosis led to the transfer of CD80 and CD86 costimulatory ligands from maturing cDCs to TR cells. In NOD mice, Fc.IL-2 mutein treatment promoted the suppression of cDCs in the inflamed pancreas and pancreatic lymph nodes resulting in T cell anergy. Thus, IL-2 mutein-expanded TR cells have enhanced functional properties and restrict cDC function, offering promise for targeted immunotherapy use in autoimmune disease.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.11.28.568839">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.11.28.568839" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.11.28.568839">
        <p class="paperTitle">Interpretable Inflammation Landscape of Circulating Immune cells</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.11.28.568839" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.11.28.568839" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Jimenez-Gracia, L.; Maspero, D.; Aguilar-Fernandez, S.; Craighero, F.; Ruiz, S.; Marchese, D.; Caratu, G.; Elosua-Bayes, M.; Abdalfatah, M.; Sanzo-Machuca, A.; M. Corraliza, A.; Massoni-Badosa, R.; A. Tran, H.; Normand, R.; Nestor, J.; Hong, Y.; Kole, T.; van der Velde, P.; Alleblas, F.; Pedretti, F.; Aterido, A.; Banchero, M.; Soriano, G.; Roman, E.; van den Berge, M.; Salas, A.; Carrascosa, J. M.; Fernandez Nebro, A.; Domenech, E.; Canete, J.; Tornero, J.; Perez-Gisbert, J.; Choy, E.; Girolomoni, G.; Siegmund, B.; Julia, A.; Serra, V.; Elosua, R.; Tejpar, S.; Vidal, S.; Nawijn, M. C.; Marsal</p>
        <p class="info">Score: 56.0, Published: 2023-11-28 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.11.28.568839' target='https://doi.org/10.1101/2023.11.28.568839'> 10.1101/2023.11.28.568839</a></p>
        <p class="abstract">Inflammation is a biological phenomenon involved in a wide variety of physiological and pathological processes. Although a controlled inflammatory response is beneficial for restoring homeostasis, it can become unfavorable if dysregulated. In recent years, major progress has been made in characterizing acute and chronic inflammation in specific diseases. However, a global, holistic understanding of inflammation is still elusive. This is particularly intriguing, considering the crucial function of inflammation for human health and its potential for modern medicine if fully deciphered. Here, we leverage advances in the field of single-cell genomics to delineate the full spectrum of circulating immune cell activation underlying inflammatory processes during infection, immune-mediated inflammatory diseases and cancer. Our single-cell atlas of &gt;2 million peripheral blood mononuclear cells from 356 patients and 18 diseases allowed us to learn a foundation model of inflammation in circulating immune cells. The atlas expanded our current knowledge of the biology of inflammation of acute (e.g. inflammatory bowel disease, sepsis) and chronic (e.g. cirrhosis, asthma, and chronic obstructive pulmonary disease) disease processes and laid the foundation to develop a precision medicine framework using unsupervised as well as explainable machine learning. Beyond a disease-centered classification, we charted altered activity of inflammatory molecules in peripheral blood cells, depicting functional biomarkers to further understand mechanisms of inflammation. Finally, we have laid the groundwork for developing precision medicine diagnostic tools for patients experiencing severe acute or chronic inflammation by learning a classifier for inflammatory diseases, presenting cells in circulation as a powerful resource for patient stratification.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.11.13.566860">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.11.13.566860" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.11.13.566860">
        <p class="paperTitle">Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.11.13.566860" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.11.13.566860" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Yang, S.; Yu, Y.; Xu, Y.; Jian, F.; Song, W.; Yisimayi, A.; Wang, P.; Wang, J.; Liu, J.; Yu, L.; Niu, X.; Wang, J.; Wang, Y.; Shao, F.; Jin, R.; Wang, Y.; Cao, Y.</p>
        <p class="info">Score: 328.8, Published: 2023-11-17 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.11.13.566860' target='https://doi.org/10.1101/2023.11.13.566860'> 10.1101/2023.11.13.566860</a></p>
        <p class="abstract">While the BA.2.86 variant demonstrated significant antigenic drift and enhanced ACE2 binding affinity, its ability to evade humoral immunity was relatively moderate compared to dominant strains like EG.5 and HK.3. However, the emergence of a new subvariant, JN.1 (BA.2.86.1.1), which possesses an additional spike mutation, L455S, compared to BA.2.86, showed a markedly increased prevalence in Europe and North America, especially in France. Here, we found that L455S of JN.1 significantly enhances immune evasion capabilities at the expense of reduced ACE2 binding affinity. This mutation enables JN.1 to effectively evade Class 1 neutralizing antibodies, offsetting BA.2.86s susceptibility and thus allowing it to outcompete both its precursor BA.2.86 and the prevailing variants HV.1 (XBB.1.5&#43;L452R&#43;F456L) and JD.1.1 (XBB.1.5&#43;L455F&#43;F456L&#43;A475V) in terms of humoral immune evasion. The rapid evolution from BA.2.86 to JN.1, similar to the earlier transition from BA.2.75 to CH.1.1, highlights the importance of closely monitoring strains with high ACE2 binding affinity and distinct antigenicity, despite their temporarily unremarkable immune evasion capabilities. Such strains could survive and transmit at low levels, since their large antigenic distance to dominant strains allow them to target distinct populations and accumulate immune-evasive mutations rapidly, often at the cost of receptor binding affinity.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
         Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
